Predicting leaky heart valves with 3D printing

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have created a novel 3D printing workflow that allows cardiologists to evaluate how different valve sizes will interact with each patient's unique anatomy, before the medical procedure is actually performed. This protocol uses CT scan data to produce physical models of individual patients' aortic valves, in addition to a "sizer" device to determine the perfect replacement valve size. The work was performed in collaboration with researchers and physicians from Brigham and Women's Hospital, The University of Washington, Massachusetts General Hospital, and the Max Planck Institute of Colloids and Interfaces, and is published in the Journal of Cardiovascular Computed Tomography.

"If you buy a pair of shoes online without trying them on first, there's a good chance they're not going to fit properly. Sizing replacement TAVR valves poses a similar problem, in that doctors don't get the opportunity to evaluate how a specific valve size will fit with a patient's anatomy before surgery," said James Weaver, Ph.D., a Senior Research Scientist at the Wyss Institute who is a corresponding author of the paper. "Our integrative 3D printing and valve sizing system provides a customized report of every patient's unique aortic valve shape, removing a lot of the guesswork and helping each patient receive a more accurately sized valve."

When a patient needs a replacement heart valve, they frequently get a CT scan, which takes a series of X ray images of the heart to create a 3D reconstruction of its internal anatomy. While the outer wall of the aorta and any associated calcified deposits are easily seen on a CT scan, the delicate "leaflets" of tissue that open and close the valve are often too thin to show up well. "After a 3D reconstruction of the heart anatomy is performed, it often looks like the calcified deposits are simply floating around inside the valve, providing little or no insight as to how a deployed TAVR valve would interact with them," Weaver explained.

To solve that problem, Ahmed Hosny, who was a Research Fellow at the Wyss Institute at the time, created a software program that uses parametric modeling to generate virtual 3D models of the leaflets using seven coordinates on each patient's valve that are visible on CT scans. The digital leaflet models were then merged with the CT data and adjusted so that they fit into the valve correctly. The resulting model, which incorporates the leaflets and their associated calcified deposits, was then 3D printed into a physical multi-material model.

The team also 3D printed a custom "sizer" device that fits inside the 3D-printed valve model and expands and contracts to determine what size artificial valve would best fit each patient. They then wrapped the sizer with a thin layer of pressure-sensing film to map the pressure between the sizer and the 3D-printed valves and their associated calcified deposits, while gradually expanding the sizer.

"We discovered that the size and the location of the calcified deposits on the leaflets have a big impact on how well an artificial valve will fit into a calcified one," said Hosny, who is currently at the Dana-Farber Cancer Institute. "Sometimes, there was just no way a TAVR valve would fully seal a calcified valve, and those patients could actually be better off getting open-heart surgery to obtain a better-fitting result."

In addition, the multi-material design of the 3D-printed valve models, which incorporate flexible leaflets and rigid calcified deposits into a fully integrated shape, could much more accurately mimic the behavior of real heart valves during artificial valve deployment, as well as provide haptic feedback as the sizer is expanded.

The team tested their system against data from 30 patients who had already undergone TAVR procedures, 15 of whom had developed leaks from valves that were too small. The researchers predicted, based on how well the sizer fit into the 3D printed models of their aortic valves, what size valve each patient should have received, and whether they would experience leaks after the procedure. The system was able to successfully predict leak outcome in 60-73% of the patients (depending on the type of valve the patient had received), and determined that 60% of the patients had received the appropriate size of valve.

"Being able to identify intermediate- and low-risk patients whose heart valve anatomy gives them a higher probability of complications from TAVR is critical, and we've never had a non-invasive way to accurately determine that before," said co-author Beth Ripley, M.D., Ph.D, an Assistant Professor in the Department of Radiology at the University of Washington who was a Cardiovascular Imaging Fellow at Brigham and Women's Hospital when the study was done. "Those patients might be better served by surgery, as the risks of an imperfect TAVR result might outweigh its benefits." Additionally, being able to physically simulate the procedure might inform future iterations of valve designs and deployment approaches.

The team has made their leaflet modeling software and 3D printing protocol freely available online for researchers or clinicians who wish to use them. They hope their project will serve as a springboard for evolvable biomedical design that keeps pace with the market's state of the art.

"At the core of the personalized medicine challenge is the realization that one medical treatment will not serve all patients equally well, and that therapies should be tailored to the individual," said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, as well as Professor of Bioengineering at Harvard's School of Engineering and Applied Sciences. "This principle applies to medical devices as well as drugs, and it is exciting to see how our community is innovating in this space and attempting to translate new personalized approaches from the lab and into the clinic."